Phase I/II trial of AST-VAC2 in patients with non-small cell lung cancer.
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2016
At a glance
- Drugs VAC 2 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 14 Nov 2016 According to an Asterias Biotherapeutics media release, preparation of a regulatory dossier to support execution of this study is underway with submission to the UK Medicines and Healthcare Products Agency (MHRA) planned early in the first quarter of 2017.
- 04 Nov 2016 According to Asterias media release, the company planned to initiate this trial in the first half of 2017.
- 29 Mar 2016 According to Asterias media release, the company expected to begin enrollment in this study in early 2017.